ArticleEuropean journal of breast health2022
Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab.
Article in European journal of breast health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis.Clinical rheumatology · 2026Article
- Personalized Treatment Outcomes in Idiopathic Granulomatous Mastitis: A Retrospective Study of Ninety-Two Patients.European journal of breast health · 2026Article
- Cystic neutrophilic granulomatous mastitis: radiologic features and clinical management.Journal of medical case reports · 2026Article
- Article
- Prolactin-Linked Plasma Cell-Macrophage Immune Phenotype in Synchronous Bilateral Plasma Cell Mastitis: A Two-Center Prediction Study with Tissue Correspondence.International journal of women's health · 2026Article
- Single-Cell RNA Sequencing Reveals the Immune Landscape of Granulomatous Mastitis.Inflammation · 2025Article
- Article
- Rat Model of Cystic Neutrophilic Granulomatous Mastitis by Corynebacterium Kroppenstedtii.Journal of inflammation research · 2025Article
- Presentation and Management of Granulomatous Mastitis in the United States: Results of an American Society of Breast Surgeons Registry Study.Annals of surgical oncology · 2024Article
- Editorial: Reviews and advances in inflammatory diseases and the tumor necrosis factor.Frontiers in cell and developmental biology · 2024Article
- Immune Markers and Inflammatory Cytokines in Granulomatous Lobular Mastitis: A Case-Control Study.Journal of inflammation research · 2024Article
- Novel insights: crosstalk with non-puerperal mastitis and immunity.Frontiers in immunology · 2024Review
- What predicts the recurrence in ıdiopathic granulomatous mastitis?Clinical rheumatology · 2023Article
- Tristetraprolin promotes survival of mammary progenitor cells by restraining TNFα levels.Frontiers in cell and developmental biology · 2023Article
- Cystic Neutrophilic Granulomatous Mastitis Treatment with Consecutive Dapsone and Adalimumab.Dermatopathology (Basel, Switzerland) · 2022Article
- Differential expression profiles of miRNA in granulomatous lobular mastitis and identification of possible biomarkers.Experimental and therapeutic medicine · 2022Article
- Cystic Neutrophilic Granulomatous Mastitis: A Cytological Evaluation.Journal of cytologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lipid vacuoles rimmed by neutrophils with an outer cuff of epithelioid histiocytes/granulomas, with inconsistent presence of Coryneform bacteria within the vacuoles. There is no consensus on the treatment for either IGM or CNGM, which may be managed surgically with wide local excision or mastectomy or medically with antibiotics, steroids, and steroid-sparing immunosuppressive agents. We present a 30-year-old woman with plaque psoriasis and CNGM whose breast symptoms resolved after treatment with the tumor necrosis factor alpha (TNF-α) inhibitor adalimumab, which has not previously been described as a treatment option for CNGM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.